NCT05669807View on ClinicalTrials.gov

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

December 31, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2025

Conditions
Second Line Treatment of Gastric Cancer
Interventions
DRUG

Camrelizumab

200mg d1, the first day, every 14 days as a cycle

DRUG

Albumin-Bound Paclitaxel

100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle

DRUG

Irinotecan

180 mg/m2, the first day, every 14 days as a cycle

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER